Celldex brings out the ax in wake of breast cancer drug disaster, chopping a quarter of its staff

Celldex Therapeutics $CLDX is restructuring and cutting back in the aftermath of a disastrous Phase IIb readout. The company — no stranger to misfortune — reported late Thursday that it is cutting 59 positions from its 2018 budgeted workforce, leaving it with 148 employees.